Navigation Links
Statement From the Consumer Healthcare Products Association on Proposed New 'Third Class' of Medicines
Date:11/14/2007

ines provides an important, cost-effective, and convenient benefit to consumers and to public health. Consumer access to NRT has resulted in tens of thousands of people quitting smoking every year, translating into an annual $2 billion social benefit. Additionally, due to the switch of a number of vaginal antifungals for recurrence of infections, women's visits to the doctor for this condition were reduced by 15 percent in the first four years post-switch.

"We believe that existing statutory and regulatory laws offer sufficient flexibility for companies and FDA to explore new or different approaches to moving prescription medicines to nonprescription status. We are committed to providing innovative solutions to enhance consumer access to OTC medicines."

CHPA is the 126-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplement products.

http://www.chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...ng point for behavior change, DES MOINES, Iowa, O...,Americans (51 percent) believe there are good thi...r changes are needed, according to the 2008,EBRI H...oday by the,Employee Benefit Research Institute an...derwritten by the Principal Financial Group(R)., ...
(Date:10/10/2008)...dentialing Center (ANCC) has designated Geisinger ...s came via a conference call to hospital administr...and applause., GMC joins an elite group of only 1...n the United States that have achieved Magnet stat...s recognition., "Achieving Magnet designation is ...
(Date:10/10/2008)... blame , , FRIDAY, Oct. 10 (HealthDay Ne...ve diabetes, being depressed was associated with a..., Publishing in the October issue of the Journal...he University of Washington tracked 10,704 Medicar...d diabetes and were enrolled in a disease manageme...
(Date:10/10/2008)...llence in the implementation of electronic health ...agement Systems Society (HIMSS) announces the reci...onal, Ambulatory and Community Health Organization...L (PRWEB) October 10, 2008 -- Honoring excellence ... (EHRs), the Healthcare Information and Managemen...
Breaking Medicine News(10 mins):Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5
...versity of Pennsylvania report the first ever use ... multiple body organs.// Mucopolysaccharidosis VII... called lysosomal storage diseases. Other examples...PS involves an enzyme defect, leading to blindness...
...e new high-tech abortion drug being freely sold ov...f do-it-yourself-abortions,// experts fear. Alread...tives, they claim, and even as the pharmaceutical ...ar meals ostensibly to introduce them to “the revo...
...gh discovery, American researchers have found some...pond to stimuli in the womb. There have always bee...mens such as 'hothousing',// where the baby is rea...he womb. However, the effectiveness of inventions...
...emical Laboratory (NCL) and Emcure Pharmaceuticals...ith a new drug for the treatment of hypertension. ...sday,// NCL director Sivaram and Emcure managing d...odipine, a product of their collaborative research...
Other Medicine News:Health News:Abortion made easy pill causes alarm in state 2
(Date:10/8/2008)..., France, Oct. 8 /- Vical Incorporate...inical data and new nonclinical data,demonstrating...roadly,applicable in DNA- and protein-based infect...cines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,... present the data today,Wednesday, October 8, at ...
(Date:10/7/2008)...aluates the efficacy of new device for detecting p...ing colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswir...Annual Scientific Meeting in Orlando (ACG 2008), r...ented results from a,multi-institutional clinical ...(R) Retroscope(R), a new device that is designed t...
(Date:10/7/2008)...Showed Larazotide Acetate Prevented Immunologic Ch...s with Celiac Disease, Additional Data Indicates P...ORLANDO, Fla., Oct. 7 /- Alba Therape...cal studies this week at the American,College of G...ng. Data from,study CLIN 1001-004, the first Phase...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Scientific M...Call/ -- Ironwood,Pharmaceuticals, Inc. (formerly ...E: FRX ) today announced the presentation of resu...safety and efficacy in 420 patients with,irritable...s of the data,indicates that once- daily oral dosi...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5AMERIGROUP Corporation to Host Investor Day 1320 1AMERIGROUP Corporation to Host Investor Day 1320 2Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes 1317 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 2Monsanto Company Signs Share Subscription Agreement With Devgen 594 3Non Stick Gum Something to Chew On 1313 1
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish.
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees.
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish.
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish.
Medicine Products: